Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Apr 27

PMID 38672645

Authors

Pasquale Niscola

Valentina Gianfelici

Marco Giovannini

Daniela Piccioni

Carla Mazzone

Paolo de Fabritiis

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.

Citing Articles

Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes.

Wang M, Liao C, Wei X, Xie Y, Han P, Yu Y PLoS One. 2025; 20(3):e0315408.

PMID: 40073065 PMC: 11902259. DOI: 10.1371/journal.pone.0315408.

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.

Niscola P, Gianfelici V, Catalano G, Giovannini M, Mazzone C, Noguera N Curr Oncol. 2024; 31(11):6632-6658.

PMID: 39590121 PMC: 11592437. DOI: 10.3390/curroncol31110490.

Genetic predisposition to myelodysplastic syndrome: Genetic counseling and transplant implications.

Liu Y, Calzone K, McReynolds L Semin Hematol. 2024; 61(6):370-378.

PMID: 39443230 PMC: 11661499. DOI: 10.1053/j.seminhematol.2024.09.003.

References

Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa E . Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020; 172(8):513-522. DOI: 10.7326/M19-0916. View

Ning Y, Zhang Y, Kallen M, Emadi A, Baer M . Cytogenetics and molecular genetics of myelodysplastic neoplasms. Best Pract Res Clin Haematol. 2023; 36(4):101512. DOI: 10.1016/j.beha.2023.101512. View

Acha P, Mallo M, Sole F . Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. Cancers (Basel). 2022; 14(22). PMC: 9688702. DOI: 10.3390/cancers14225531. View

Patnaik M, Santini V . Targeting ineffective hematopoiesis in myelodysplastic syndromes. Am J Hematol. 2021; 97(2):171-173. DOI: 10.1002/ajh.26416. View

Gurnari C, Robin M, Godley L, Drozd-Sokolowska J, Wlodarski M, Raj K . Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023; 10(12):e994-e1005. DOI: 10.1016/S2352-3026(23)00265-X. View

Khanna V, Lu R, Kumar J, Molina A, Stehr H, Spiteri E . The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leuk Res. 2023; 136:107433. DOI: 10.1016/j.leukres.2023.107433. View

Kanagal-Shamanna R, Beck D, Calvo K . Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy. Annu Rev Pathol. 2023; 19:479-506. DOI: 10.1146/annurev-pathmechdis-051222-122724. View

Loeza-Uribe M, Hinojosa-Azaola A, Sanchez-Hernandez B, Crispin J, Apodaca-Chavez E, Ferrada M . VEXAS syndrome: Clinical manifestations, diagnosis, and treatment. Reumatol Clin (Engl Ed). 2023; 20(1):47-56. DOI: 10.1016/j.reumae.2023.12.004. View

Larson R . Therapy-related myeloid neoplasms. Haematologica. 2009; 94(4):454-9. PMC: 2663607. DOI: 10.3324/haematol.2008.005157. View

10.

Oliva E, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E . A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes. J Clin Med. 2022; 11(3). PMC: 8836890. DOI: 10.3390/jcm11030895. View

11.

Tran T, Siddon A . Molecular findings in myeloid neoplasms. Int J Lab Hematol. 2023; 45(4):442-448. DOI: 10.1111/ijlh.14118. View

12.

Efficace F, Cottone F, Oswald L, Cella D, Patriarca A, Niscola P . The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia. 2020; 34(9):2451-2459. PMC: 7509847. DOI: 10.1038/s41375-020-0746-8. View

13.

DeZern A, Greenberg P . The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes. Blood. 2023; 142(26):2258-2267. DOI: 10.1182/blood.2023020081. View

14.

Rodriguez-Sevilla J, Colla S . T-cell dysfunctions in myelodysplastic syndromes. Blood. 2024; 143(14):1329-1343. DOI: 10.1182/blood.2023023166. View

15.

Campagna A, Della Porta M . Mutational screening to improve the transplantation decision-making process in MDS. Hematology Am Soc Hematol Educ Program. 2023; 2023(1):73-76. PMC: 10727083. DOI: 10.1182/hematology.2023000516. View

16.

Vijenthira A, Starkman R, Lin Y, Stanworth S, Bowen D, Harrison L . Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome. Transfusion. 2022; 62(7):1355-1364. DOI: 10.1111/trf.16946. View

17.

Jiang M, Chen M, Liu Q, Jin Z, Yang X, Zhang W . SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process. Front Oncol. 2023; 13:1116438. PMC: 10063959. DOI: 10.3389/fonc.2023.1116438. View

18.

Wang C, Sallman D . Therapeutic approaches for the management of higher risk myelodysplastic syndromes. Leuk Lymphoma. 2022; 64(3):511-524. DOI: 10.1080/10428194.2022.2140287. View

19.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

20.

Moreno Berggren D, Garelius H, Willner Hjelm P, Nilsson L, Rasmussen B, Weibull C . Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective. Leukemia. 2023; 37(5):1103-1112. PMC: 10169633. DOI: 10.1038/s41375-023-01864-6. View